Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization and Bioactivity of Nanovesicles Recovered From Industrial Cheesemaking Whey Wastewater.

Journal of food science·2026
Same author

Sertoli cells as potential agents against mycobacterial infections.

BMC microbiology·2026
Same author

A novel spray-dried milk extracellular vesicles formulation with long-term immunomodulatory activity and functional stability.

Scientific reports·2026
Same author

Toward indole postbiotics precision therapy via AI-powered drug delivery technologies.

Current opinion in immunology·2025
Same author

Preface.

Recent advances in drug delivery and formulation·2025
Same author

Updates on <i>Candida albicans</i> infections: pathogenesis, resistance, and emerging nanopharmaceutical strategies.

Expert review of anti-infective therapy·2025
Same journal

Corrigendum to "Alkyl Length Effects on the DNA Transport Properties of Cu (II) and Zn(II) Metallovesicles: An <i>In Vitro</i> and <i>In Vivo</i> Study".

Journal of drug delivery·2020
Same journal

Dry Powder and Budesonide Inhalation Suspension Deposition Rates in Asthmatic Airway-Obstruction Regions.

Journal of drug delivery·2019
Same journal

Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds.

Journal of drug delivery·2019
Same journal

Rate of Drug Coating Dissolution Determines In-Tissue Drug Retention and Durability of Biological Efficacy.

Journal of drug delivery·2019
Same journal

Alkyl Length Effects on the DNA Transport Properties of Cu (II) and Zn(II) Metallovesicles: An <i>In Vitro</i> and <i>In Vivo</i> Study.

Journal of drug delivery·2018
Same journal

Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats.

Journal of drug delivery·2018
See all related articles

Related Experiment Video

Updated: May 2, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

67.2K

Development of Risperidone PLGA Microspheres.

Susan D'Souza1, Jabar A Faraj2, Stefano Giovagnoli3

  • 1Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA.

Journal of Drug Delivery
|March 12, 2014
PubMed
Summary
This summary is machine-generated.

Biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres offer sustained Risperidone delivery for schizophrenia treatment. These formulations improve drug effectiveness and reduce the need for combination oral therapies.

More Related Videos

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology
05:21

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology

Published on: May 16, 2022

2.7K
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.4K

Related Experiment Videos

Last Updated: May 2, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

67.2K
Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology
05:21

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology

Published on: May 16, 2022

2.7K
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.4K

Area of Science:

  • Pharmaceutics
  • Biomaterials Science
  • Pharmacology

Background:

  • Schizophrenia treatment often requires combination therapy.
  • Risperidone is a key antipsychotic medication.
  • Sustained drug delivery systems aim to improve patient compliance and therapeutic outcomes.

Purpose of the Study:

  • To design and evaluate biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres for sustained Risperidone delivery.
  • To explore the potential of these microspheres to avoid combination therapy for schizophrenia.
  • To investigate the impact of PLGA copolymer composition on drug release kinetics and in vivo behavior.

Main Methods:

  • Preparation of four Risperidone-loaded PLGA microsphere formulations using 50:50 and 75:25 PLGA copolymers.
  • In vitro characterization of microsphere properties.
  • In vivo pharmacokinetic studies in Sprague-Dawley rats at 20 and 40 mg/kg doses.
  • Simulation of multiple dosing regimens (weekly and 15-day).

Main Results:

  • All formulations demonstrated an initial burst release followed by sustained Risperidone release.
  • Microspheres made with 75:25 PLGA exhibited longer duration of action and higher cumulative AUC compared to 50:50 PLGA formulations.
  • Multiple dosing simulations showed pulsatile drug release, achieving steady state by the second dose.
  • PLGA composition and molecular weight influenced in vivo drug release profiles.

Conclusions:

  • Biodegradable PLGA microspheres are suitable for developing sustained-release Risperidone formulations.
  • These formulations can potentially eliminate the need for combination oral therapy in schizophrenia treatment.
  • PLGA microspheres offer tailored in vivo behavior, enhancing pharmacological effectiveness and reducing washout periods.